The following is a summary of "Sex differences in outcomes in patients with acute myocardial infarction," published in the ...

A potential strategy introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within ...

Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the United States ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...

Febuxostat does not appear to increase the risk for major adverse cardiovascular events when compared with no urate-lowering ...

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to ...

Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval from the United States Food ...

A study has found that moderate-to-severe obstructive sleep apnea increases risk for incident myocardial infarction between 12 and 5:59 AM.

No-touch' vein harvesting significantly reduces the risk of graft failure up to three years after coronary artery bypass ...

The pharmaceutical company has been awarded the final approval for the manufacture of Niacin Extended-Release Tablets USP in ...

In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins. HealthDay News — For patients with myocardial ...